GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pharmocann Global Ltd (XTAE:PMCN-M) » Definitions » Capex-to-Operating-Cash-Flow

Pharmocann Global (XTAE:PMCN-M) Capex-to-Operating-Cash-Flow : 0.00 (As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Pharmocann Global Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Pharmocann Global's Capital Expenditure for the three months ended in Dec. 2023 was ₪0.00 Mil. Its Cash Flow from Operations for the three months ended in Dec. 2023 was ₪0.00 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


Pharmocann Global Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Pharmocann Global's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmocann Global Capex-to-Operating-Cash-Flow Chart

Pharmocann Global Annual Data
Trend Dec09 Dec10 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Pharmocann Global Quarterly Data
Dec17 Jun18 Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Dec23
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Pharmocann Global's Capex-to-Operating-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, Pharmocann Global's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmocann Global's Capex-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pharmocann Global's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Pharmocann Global's Capex-to-Operating-Cash-Flow falls into.



Pharmocann Global Capex-to-Operating-Cash-Flow Calculation

Pharmocann Global's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-0.033) / -4.881
=N/A

Pharmocann Global's Capex-to-Operating-Cash-Flow for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharmocann Global  (XTAE:PMCN-M) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Pharmocann Global Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Pharmocann Global's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmocann Global (XTAE:PMCN-M) Business Description

Traded in Other Exchanges
N/A
Address
Ramat Yishai, PO Box 305, Kiryat Tivon, ISR, 3601201
Pharmocann Global Ltd is an Israel-based company engaged in producing medical-related cannabis products which include oil, ointments, tablets, inhalers, rectal and vaginal suppositories, and pre-rolled cigarettes of various types of THC/CBD strains.

Pharmocann Global (XTAE:PMCN-M) Headlines

No Headlines